AN2 Therapeutics, Inc. ((ANTX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AN2 Therapeutics, Inc. is conducting a Phase 1 clinical trial titled ‘A Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998.’ The study aims to assess the safety and pharmacokinetics of AN2-502998, a new oral drug, in healthy volunteers, marking a significant step in its development.
The intervention involves administering AN2-502998, an experimental oral capsule, to participants. The study includes both single ascending dose (SAD) and multiple ascending dose (MAD) groups, with a placebo used for control.
This interventional study is randomized and double-blinded, meaning neither participants nor investigators know who receives the drug or placebo. The primary goal is basic science, focusing on understanding the drug’s effects.
The study began on May 31, 2025, and is currently recruiting participants. The last update was submitted on September 5, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates.
This update could influence AN2 Therapeutics’ stock performance as investors monitor the trial’s progress and potential outcomes. Successful results could enhance investor confidence and position AN2-502998 favorably against competitors in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.